Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION

Dasatinib dose adjustments may be necessary to manage adverse events (AEs). Multiple dasatinib dosage strengths are available, allowing adjustments to be possible. In a 2-year retrospective analysis of DASISION (Jabbour ASH 2011), higher response rates were maintained for dasatinib versus imatinib and efficacy was not compromised due to dose modifications.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge E. Cortes, Andreas Hochhaus, Hagop Kantarjian, Fran çois Guilhot, Vamsi Kota, Timothy P. Hughes, Suresh Shelat, Oumar Sy, Elias Jabbour Source Type: research